Eli Lilly Stock Surges After Diabetes, Weight-Loss Sales Wallop ...

Aug 8, 2024 · Eli Lilly stock briefly retook its 50-day line Thursday after its diabetes and weight-loss drugs walloped sales expectations, leading the company to hike its full-year outlook. ↑ X

CouponFollow Extension

10%
OFF

Eli Lilly Surges 10% After Diabetes, Weight-Loss Sales Wallop

4 weeks from now

Eli Lilly stock rocketed Thursday after its diabetes and weight-loss drugs walloped expectations, leading to a guidance hike. ... Eli Lilly Surges 10% After Diabetes, Weight-Loss Sales Wallop ...

msn.com

$3
OFF

Eli Lilly Boosts Sales Forecast By $3bn As Diabetes And Weight Loss ...

4 weeks from now

Aug 9, 2024 · Eli Lilly raised its full-year sales forecast by $3bn to the range of $45.4bn to $46.6bn. The company cited strong performance from Zepbound, as well as its type 2 …

yahoo.com

36%
OFF

Eli Lilly's Weight-Loss Drugs Fuel Beat-And-Raise Quarter

4 weeks from now

Aug 8, 2024 · In the three months ended June 30, Eli Lilly's revenue increased 36% year-over-year to $11.3 billion, driven by demand for its weight-loss drugs, Mounjaro and Zepbound, as …

kiplinger.com

$2
OFF

Weight-loss Drug Drives Eli Lilly To Raise 2024 Sales Forecast By $2 ...

4 weeks from now

Apr 30, 2024 · Eli Lilly and Danish rival Novo Nordisk (NYSE: NVO) are racing to increase production in a weight-loss market estimated to reach at least $100 billion by decade's end. …

investing.com

9%
OFF

Eli Lilly Stock Slides Pre-Market On Weight-Loss Drug Sales Miss, …

4 weeks from now

Oct 30, 2024 · Eli Lilly & Co. shares fell over 9% in pre-market trading Wednesday after the company’s third-quarter profit and revenue missed analyst expectations by a wide …

stocktwits.com

$600
OFF

Eli Lilly's Rare Sales Miss For Weight-Loss Drug Sends Shares …

4 weeks from now

Oct 30, 2024 · The drug is sold under the brand name Mounjaro for both diabetes and weight loss outside the U.S. Lilly trimmed the upper end of its full-year sales forecast by $600 million to …

usnews.com

6%
OFF

The Weight-Loss Battle That Could Rattle Eli Lilly's $100 Billion …

4 weeks from now

Dec 5, 2024 · Eli Lilly stock tumbled more than 6% on Oct. 30 after sales of Mounjaro and Zepbound missed third-quarter expectations. The duo generated a combined $4.37 billion in …

investors.com

33%
OFF

Lilly Rides Weight-loss Drug Wave, Set For Eighth ... - TradingView

4 weeks from now

1 day ago · ** Weight loss drugmaker Eli Lilly's NYSE:LLY shares have risen about 33% this year - set for the eighth successive year of gains ** LLY, already the world's most valuable …

tradingview.com

121%
OFF

Eli Lilly Plummets On Rare — But 'Big' — Sales Miss For Diabetes ...

4 weeks from now

Eli Lilly stock crashed Wednesday after the pharma giant cut its 2024 outlook following a "big" miss for its diabetes and weight-loss drugs. ... Mounjaro sales rocketed 121% to $3.11 billion. …

msn.com

24%
OFF

Is Eli Lilly Stock A Buy? - The Motley Fool

4 weeks from now

3 days ago · Reports indicate he was actually taking Eli Lilly's (LLY-0.24%) weight-loss drug Mounjaro. Eli Lilly's stock has been a strong winner over the past few years, powered by its …

fool.com

19%
OFF

Will Weight-Loss, Diabetes Drugs Drive LLY Stock Into $1 Trillion …

4 weeks from now

Feb 16, 2024 · Eli Lilly's weight-loss and diabetes treatments Zepbound and Mounjaro should drive LLY stock much higher, said a Morgan Stanley analyst. ... Lilly's adjusted profit rose 19% …

investors.com

64%
OFF

Healthcare Stocks Like Eli Lilly Are Set To Surge In 2025: Citi ...

4 weeks from now

5 days ago · Citi's analysts seem to agree, forecasting returns of 64% for Eli Lilly, which carries the biggest weight in the sector at 12%. "Although policy controversy remains, we think this is …

businessinsider.com

18%
OFF

Novo Nordisk Stock Crashes 18% After New Obesity Drug Misses …

4 weeks from now

Dec 20, 2024 · Novo Nordisk stock crashed Friday after the pharmaceutical giant's next-generation weight-loss drug missed expectations in a highly anticipated study.Shares of rivals …

investors.com

FAQs about Eli Lilly Stock Surges After Diabetes, Weight-Loss Sales Wallop ... Coupon?

Why did Eli Lilly stock crash Wednesday?

Eli Lilly (LLY) stock crashed Wednesday after the pharma giant cut its 2024 outlook following a "big" miss for its popular diabetes and weight-loss drugs. The company's drug, tirzepatide, provides the backbone for diabetes treatment Mounjaro and weight-loss drug Zepbound. In the September quarter, Mounjaro sales rocketed 121% to $3.11 billion. ...

Why did Eli Lilly's stock close 6% lower on Wednesday?

Eli Lilly on Wednesday fell short of profit and revenue expectations for the third quarter, weighed down by disappointing sales of its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro, and slashed its full-year adjusted profit guidance. The company's stock closed more than 6% lower on Wednesday. ...

Is Eli Lilly stock a buy?

Eli Lilly has been riding the weight-loss drug wave. The company's weight-loss drugs have been shown to be more effective than rival Ozempic. The stock currently trades at an attractive valuation. ...

Why did Eli Lilly stock jump to a record high?

Eli Lilly (LLY) stock jumped to a record high on Tuesday after clinical trial results showed tirzepatide—the active ingredient in Lilly's injectable weight-loss drug Zepbound and diabetes treatment Mounjaro—lowered patients' risk of developing type 2 diabetes by 94%. ...

Why did Eli Lilly lose $70 billion?

(Reuters) -Eli Lilly's high profile weight-loss and diabetes drugs fell short of Wall Street sales estimates on Wednesday as supplies sat in warehouses, a 180-degree turn for the company after long struggling to meet outsized demand. Lilly shares were off 8%, wiping out nearly $70 billion from the Indianapolis-based drugmaker's market value. ...

Why did Eli Lilly share prices fall?

Eli Lilly shares fell sharply in early Wednesday trading after the pharmaceutical giant posted weaker-than-expected third-quarter earnings, while slashing its full-year profit forecast, following disappointing sales of its blockbuster weight loss treatments. ...